Answers are grounded in this paper and cite their sources.
Myasthenia gravis (MG) is a chronic autoimmune disease that causes fluctuating muscle weakness. This study aimed to investigate the intricate relationship between myasthenia gravis and psychiatric comorbidities, aiming to elucidate their bidirectional causality, and to assess the effectiveness of therapeutic interventions. The research included 49 MG patients diagnosed with depressive disorders who were followed-up for six months and assessed with depression and anxiety scales, along with MG severity. The study employed linear mixed models and paired t-tests to analyze the associations between myasthenia gravis progression and psychiatric symptoms. The findings demonstrated a statistically significant correlation between the severity of myasthenia gravis and both depression and anxiety scores. A one-point decrease in Hamilton Depression Rating Scale (HAM-D) corresponded to a 0.5-point reduction in the Quantitative Myasthenia Gravis (QMG) score. The study underscores the importance of integrated treatment that addresses physical and psychological aspects for effective myasthenia gravis management and overall well-being.
No takes yet. Share an insight, caveat, or question.
Mihalache et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: